Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 10/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 10/20 | 0.52 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.40 |
| ▸ | IKZF2 | Q9UKS7 | 8/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23541289 | 1.00 | DDB1 (0.52) | DDB1CRBNIKZF1IKZF2HDAC8 | |
| SCHEMBL31397073 | 0.96 | DDB1 (0.51) | DDB1CRBNIKZF1IKZF2HDAC8 | |
| SCHEMBL29347197 | 0.96 | DDB1 (0.47) | DDB1CRBNIKZF1IKZF2HDAC8 | |
| SCHEMBL22502565 | 0.93 | DDB1 (0.50) | DDB1CRBNIKZF1IKZF2 | |
| SCHEMBL22525513 | 0.92 | DDB1 (0.49) | DDB1CRBNIKZF1IKZF2HDAC8 | |
| SCHEMBL31397215 | 0.91 | DDB1 (0.49) | DDB1CRBNIKZF1IKZF2HDAC8 | |
| SCHEMBL23540339 | 0.91 | DDB1 (0.41) | DDB1CRBNIKZF1IKZF2HDAC8 | |
| SCHEMBL25036957 | 0.91 | DDB1 (0.51) | DDB1CRBNIKZF1IKZF2HDAC8 | |
| SCHEMBL31333324 | 0.89 | DDB1 (0.49) | DDB1CRBNIKZF1IKZF2HDAC8 | |
| SCHEMBL23540196 | 0.89 | DDB1 (0.40) | DDB1CRBNIKZF1IKZF2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250302815-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | CALICO LIFE SCIENCES LLC | 2025-10-02 | — | — | US | disclosed |
| US-20240383886-A1 | Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof | ABBVIE INC. | 2024-11-21 | — | — | US | disclosed |
| WO-2024233846-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4384512-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | Calico Life Sciences LLC (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-116194453-A | Protein tyrosine phosphatase degrading agent and method of use thereof | 卡里科生命科学有限责任公司 | 2023-05-30 | — | — | CN | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4168407-A1 | BRAF DEGRADERS | C4 Therapeutics, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| CN-115996719-A | BRAF degradation agent | C4医药公司 | 2023-04-21 | — | — | CN | disclosed |
| WO-2023059792-A1 | CORONAVIRUS NON-STRUCTURAL PROTEIN 3 DEGRADING COMPOUNDS | C4 THRAPEUTICS, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023019166-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | CALICO LIFE SCIENCES LLC (US) | 2023-02-16 | — | — | WO | disclosed |
| EP-4077319-A1 | PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF | Calico Life Sciences LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021127586-A1 | PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559492-B2 | BRAF degraders | BRAF, NRAS, HRAS | DDB1 425/4885CRBN 32/4885IKZF1 1000/4885 |
| US-20240383886-A1 | Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof | PTPN5, PTPN1, PTPN2 | DDB1 1684/4885CRBN 182/4885IKZF1 1686/4885 |
| US-20250302815-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | PTPN1, PTPN2, PTPN18 | DDB1 1385/4885CRBN 230/4885IKZF1 1038/4885 |
| US-20230145336-A1 | BRAF DEGRADERS | BRAF, NRAS, RAF1 | DDB1 368/4885CRBN 249/4885IKZF1 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.